Therapeutic horizons for amyotrophic lateral sclerosis

Recent theories on the pathogenesis of motor neuron disease and research on motor neuron injury have resulted in new putative therapies, which include treatment with various neurotrophic factors, antioxidants and anti-excitotoxicity agents. Clinical and preclinical studies have now provided the first agents that reproducibly alter the course of amyotrophic lateral sclerosis.

[1]  P. Soubrié,et al.  Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates , 1993, Neuroscience.

[2]  M. Gurney,et al.  Benefit of vitamin E, riluzole, and gababapentin in a transgenic model of familial amyotrophic lateral sclerosis , 1996, Annals of neurology.

[3]  J. Rothstein,et al.  Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Borchelt,et al.  An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria , 1995, Neuron.

[5]  P. Aebischer,et al.  GDNF slows loss of motoneurons but not axonal degeneration or premature death of pmn/pmn mice , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[6]  H. Thoenen,et al.  Ciliary neurotrophic factor prevents the degeneration of motor neurons after axotomy , 1990, Nature.

[7]  M. Beal.  Role of excitotoxicity in human neurological disease , 1992, Current Opinion in Neurobiology.

[8]  P. Ince,et al.  [3H]d-aspartate binding sites in the normal human spinal cord and changes in motor neuron disease: a quantitative autoradiographic study , 1994, Brain Research.

[9]  Robert H. Brown,et al.  Amyotrophic lateral sclerosis: Recent insights from genetics and transgenic mice , 1995, Cell.

[10]  R. Albin,et al.  Alternative excitotoxic hypotheses , 1992, Neurology.

[11]  J. Rothstein,et al.  Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. , 1992, The New England journal of medicine.

[12]  D. Choi,et al.  Potentiated necrosis of cultured cortical neurons by neurotrophins. , 1995, Science.

[13]  H. Thoenen,et al.  Brain-derived neurotrophic factor prevents the death of motoneurons in newborn rats after nerve section , 1992, Nature.

[14]  W. Snider,et al.  Brain-derived neurotrophic factor rescues spinal motor neurons from axotomy-induced cell death , 1992, Nature.

[15]  D. Price,et al.  Ventral root avulsion: An experimental model of death of adult motor neurons , 1994, The Journal of comparative neurology.

[16]  G. Rosoklija,et al.  Brain superoxide dismutase, catalase, and glutathione peroxidase activities in amyotrophic lateral sclerosis , 1996, Annals of neurology.

[17]  W. R. Brain.  Diseases of the Nervous System , 1892, Buffalo Medical and Surgical Journal.

[18]  H. Fukuyama,et al.  Corpus callosum atrophy in amyotrophic lateral sclerosis , 1995, Journal of the Neurological Sciences.

[19]  E. Stefani,et al.  Cytotoxicity of immunoglobulins from amyotrophic lateral sclerosis patients on a hybrid motoneuron cell line. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Beal,et al.  Aging, energy, and oxidative stress in neurodegenerative diseases , 1995, Annals of neurology.

[21]  A. Novelli,et al.  Basic fibroblast growth factor protects cerebellar neurons in primary culture from NMDA and non‐NMDA receptor mediated neurotoxicity , 1993, FEBS letters.

[22]  R. H. Brown,et al.  Superoxide dismutase and familial amyotrophic lateral sclerosis: New insights into mechanisms and treatments , 1996, Annals of neurology.

[23]  Q. Yan,et al.  In vivo neurotrophic effects of GDNF on neonatal and adult facial motor neurons , 1995, Nature.

[24]  J. Lowe.  New pathological findings in amyotrophic lateral sclerosis , 1994, Journal of the Neurological Sciences.

[25]  J. Haines,et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.

[26]  V. Meininger,et al.  A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. , 1994, The New England journal of medicine.

[27]  G. Parry,et al.  A placebo‐controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis , 1996 .

[28]  C. Henderson,et al.  GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. , 1994, Science.

[29]  J. Coyle,et al.  Oxidative stress, glutamate, and neurodegenerative disorders. , 1993, Science.

[30]  J. Coyle,et al.  Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis , 1990, Annals of neurology.

[31]  A. Levey,et al.  Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis , 1995, Annals of neurology.

[32]  P. Leigh,et al.  Dose-ranging study of riluzole in amyotrophic lateral sclerosis , 1996, The Lancet.

[33]  D. Price,et al.  Ciliary neurotrophic factor prevents retrograde neuronal death in the adult central nervous system. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[34]  T. Deguchi,et al.  A null mutation in the human CNTF gene is not causally related to neurological diseases , 1994, Nature Genetics.

[35]  R. Vejsada,et al.  Neuronal deficits, not involving motor neurons, in mice lacking BDNF and/or NT4 , 1995, Nature.

[36]  A. Pestronk,et al.  Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation , 1994, Annals of neurology.

[37]  A. Volterra,et al.  Glutamate uptake inhibition by oxygen free radicals in rat cortical astrocytes , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[38]  J. Rothstein,et al.  Neuroprotective Strategies in a Model of Chronic Glutamate‐Mediated Motor Neuron Toxicity , 1995, Journal of neurochemistry.

[39]  J. Cedarbaum,et al.  Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF. , 1994, Science.

[40]  P. Ince,et al.  CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[41]  P. Bossuyt,et al.  Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. , 1995, Archives of neurology.

[42]  P N Leigh,et al.  Cytoskeletal pathology in motor neuron diseases. , 1991, Advances in neurology.

[43]  J. Rothstein,et al.  Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[44]  D. Price,et al.  Motor neurone disease and animal models , 1994, Neurobiology of Disease.

[45]  L. Cork,et al.  Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease , 1993, Cell.

[46]  E. Stefani,et al.  Evidence for autoimmunity in amyotrophic lateral sclerosis , 1993, Journal of the Neurological Sciences.

[47]  M. Hediger,et al.  Knockout of Glutamate Transporters Reveals a Major Role for Astroglial Transport in Excitotoxicity and Clearance of Glutamate , 1996, Neuron.

[48]  J. Cedarbaum,et al.  The effects of ciliary neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease , 1994, Annals of neurology.

[49]  D. Cleveland,et al.  A mutant neurofilament subunit causes massive, selective motor neuron death: Implications for the pathogenesis of human motor neuron disease , 1994, Neuron.

[50]  L. Vosshall,et al.  Circadian rhythms in drosophila can be driven by period expression in a restricted group of central brain cells , 1995, Neuron.

[51]  M. Behrens,et al.  BDNF or IGF-I potentiates free radical-mediated injury in cortical cell cultures , 1995, Neuroreport.

[52]  M. Gurney,et al.  Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. , 1994, Science.

[53]  E. Stefani,et al.  Immunoglobulins from animal models of motor neuron disease and from human amyotrophic lateral sclerosis patients passively transfer physiological abnormalities to the neuromuscular junction. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[54]  D. Borchelt,et al.  Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[55]  H. Thoenen,et al.  Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy , 1992, Nature.

[56]  J. Crapo,et al.  Requirement for Superoxide in Excitotoxic Cell Death , 1996, Neuron.

[57]  D. Cleveland.  Neuronal Growth and Death: Order and Disorder in the Axoplasm , 1996, Cell.

[58]  P. Ince,et al.  Oxidative damage to protein in sporadic motor neuron disease spinal cord , 1995, Annals of neurology.

[59]  Robert H. Brown,et al.  Superoxide Dismutase Activity, Oxidative Damage, and Mitochondrial Energy Metabolism in Familial and Sporadic Amyotrophic Lateral Sclerosis , 1993, Journal of neurochemistry.

[60]  E. Stefani,et al.  Serum antibodies to L-type calcium channels in patients with amyotrophic lateral sclerosis. , 1992, The New England journal of medicine.

[61]  A. Volterra,et al.  Peroxynitrite Inhibits Glutamate Transporter Subtypes (*) , 1996, The Journal of Biological Chemistry.